))
Novel CD20/CD3 bispecific antibodies in NHL
Manage episode 300109676 series 2838329
Inhoud geleverd door VJHemOnc. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door VJHemOnc of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.
Immunotherapies are showing increasingly promising results for the treatment of patients with non-Hodgkin lymphoma (NHL) and, in particular, bispecific antibodies have demonstrated promising clinical results in heavily pre-treated patients. Several bispecific antibodies have entered the early stages of clinical trials since the approval of the CD19/CD30 bispecific antibody blinatumomab, and recently CD20/CD3 bispecific antibodies have demonstrated encouraging response rates in patients with both aggressive and indolent NHL.
In today’s podcast, Stephen Schuster from the Perelman School of Medicine, Philadelphia, PA, Franck Morschhauser from Lille University Hospital, Lille, France, and Rajat Bannerji from the Rutgers Cancer Institute of New Jersey, Newark, NJ, discuss the latest data on CD20/CD3 bispecific antibodies for the treatment of patients with NHL, in particular talking on mosunetuzumab, CD20-TCB and odronextamab, previously known as REGN1979.
200 afleveringen
Delen
